# Atenolol Versus Losartan in the Prevention of Progressive Dilation of the Aorta in Marfan Syndrome

> **NCT01145612** · PHASE3 · UNKNOWN · sponsor: **Forteza, Albert, M.D.** · enrollment: 140 (actual)

## Conditions studied

- Marfan Syndrome

## Interventions

- **DRUG:** Losartan
- **DRUG:** Atenolol

## Key facts

- **NCT ID:** NCT01145612
- **Lead sponsor:** Forteza, Albert, M.D.
- **Sponsor class:** INDIV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-10
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2010-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01145612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01145612, "Atenolol Versus Losartan in the Prevention of Progressive Dilation of the Aorta in Marfan Syndrome". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT01145612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*